Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02485964 · ClinicalTrials.gov registry record · NA

A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine

A NA study of Prostate Cancer, sponsored by University of Arkansas.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT02485964 is a NA study of Prostate Cancer that has completed, run by University of Arkansas. The registered enrollment target is 10 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02485964, a NA study of Prostate Cancer, has completed, sponsored by University of Arkansas.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

To measure antigen-specific interferon-secretion by enzyme-linked immunospot (ELISPOT) assay, which measures antigen-specific interferon-secretion.

Conditions Studied

Prostate Cancer

Interventions

  • OTHER Blood draw

Study Locations (1)

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2015-08
Est. Completion 2018-12
Phase NA

Sponsor

University of Arkansas

318 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02485964

The ClinicalTrials.gov registry entry for NCT02485964 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.

NCT02485964 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.

Frequently Asked Questions

What is clinical trial NCT02485964 about?

NCT02485964 is a clinical study titled "A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine". To measure antigen-specific interferon-secretion by enzyme-linked immunospot (ELISPOT) assay, which measures antigen-specific interferon-secretion.

What is the current status of trial NCT02485964?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2015-08. Estimated completion is 2018-12.

What conditions does trial NCT02485964 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT02485964?

The interventions under investigation include: Blood draw (OTHER).

Who is sponsoring clinical trial NCT02485964?

This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02485964 being conducted?

This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.